Key facts
- Creasallis’s last known valuation is $3.1M (Nov 2022).
- It has raised $980K; the latest was Early Stage VC in Mar 2025.
- Notable investors include Acequia Capital, ZAKA VC, BlueYard Capital, Accelerate@Babraham, KdT Ventures — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Creasallis
- ·The full record, as it builds
Funding rounds
No funding rounds for Creasallis are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Creasallis
Developer of tumour antibody penetration technology intended to improve the penetration of antibody-based drugs into the tumour. The company specializes in biotechnology services like antibody engineering, cancer therapy, monoclonal antibodies, and bispecific antibodies, and offers monoclonal antibodies, antibody drug conjugates, bispecific antibodies, protein and peptide conjugates, and intellectual property management, enabling the biopharmaceutical industry to develop antibody medicines based on precision engineering.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2021
- Employees
- 5
- Website
- creasallis.com/
- Ownership
- Privately Held (backing)
Creasallis doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Creasallis shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Creasallis in its N-PORT filings yet. We sweep new filings monthly.